Evaluating Dose Ratio of Subcutaneous to Intravenous Immunoglobulin Therapy Among Patients With Primary Immunodeficiency Disease Switching to 20% Subcutaneous Immunoglobulin Therapy
Girishanthy Krishnarajah, MPH, MBA/MS, PhD;Jee-Yeon K. Lehmann, PhD;Brian Ellman, MBA;Rachel H. Bhak, MS;Maral DerSarkissian, PhD;Deane Leader, Jr, PhD, MBA;Ann L. Bullinger, PharmD;Mei October 21st 2016ArticleARTICLES
